Biobanks Market: Current Analysis and Forecast (2025-2033)

Biobanks are structured depositories where biological specimens in the form of tissues, blood, DNA, cells, and other biological and related health and demographic information are collected, processed, stored, and handled. These samples are maintained with standardized conditions to maintain quality and usability over time, to be used in research and clinical purposes. Also, biobanks are important in enhancing biomedical research, drug development, clinical diagnostics, and personalized medicine by providing access to high-quality, well-annotated biological specimens to the researcher. They enhance research in genomics, disease mechanisms, biomarker discovery, and therapy development, leading to significant improvements in healthcare outcomes and scientific innovation.

The Biobanks market is set to show a growth rate of about 8.8% during the forecast period (2025-2033F). The global biobanks market is accelerating due to the growing demand for personalized medicine, improved diagnostic accuracy, and the development of therapeutic methods that require high-quality biological samples. Advances in sectors such as genomics, proteomics, and biotechnology have increased the need for proper organization and long-term storage of samples. Additionally, further increases in clinical research, drug discovery, and regenerative medicine investments contribute to the market growth. Moreover, the provision of government funding, favorable regulatory environments, and increased partnerships between academic institutions, pharmaceutical firms, and research organizations are enhancing biobanking infrastructures.

Based on the product and service category, the market is categorized into consumables, software, equipment, and services. Among these, the consumables have the largest market share since they are consumed repeatedly in large amounts, replacement cycles are short, and are needed to perform routine diagnostics, procedures, and daily operations, which guarantees the same and continuous revenue. However, the software segment is expected to grow at the fastest rate, owing to the accelerated digitalization, increased use of AI-driven analytics, cloud computing, automation, and the use of data to make decisions.

Based on the sample type category, the market is categorized into human tissues, cell lines, human waste products, blood products, nucleic acids, and biological fluids. Among these, blood products have the highest market share as they are used in diagnostics, disease monitoring, transfusion services, and biomedical research, along with easy availability and standardized collection methods. However, the nucleic acids segment is expected to register faster growth in the coming years, with the accelerated development in genomics, personalized medicine, molecular diagnostics, and the increased use of PCR, sequencing, and gene-targeted therapies. Additional emphasis on the use of nucleic-acid-based samples for early disease identification and precision medicine, as well as infectious disease surveillance, will further strengthen the future of this method.

Based on the application category, the market is segmented into therapeutics, drug discovery & clinical research, clinical diagnostics, and others. Among these, clinical diagnostics holds the largest market share because it is commonly applied to hospitals, diagnostic laboratories, and medical facilities in detecting, monitoring, and preventive screening of diseases, and consequently, the volume of tests is high and recurrent. Its hegemony is further supported by the rising number of chronic and infectious diseases in the world. However, drug discovery & clinical research will likely increase faster in the next few years due to the growth in clinical trial activity, and the recent surge in the interest of precision medicine, biologics, and advanced therapeutics, all of which increase the need for high-quality biological samples. For instance, in June 2025, BioAge Labs, Inc., which is a clinical-stage biotechnology company, announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway, to enhance its drug-discovery platform.

For a better understanding of the demand of Biobanks, the market is analyzed based on its worldwide adoption in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and Rest of World. Among these, North America has the biggest market share with a high research infrastructure, high spending on healthcare, extensive genetic efforts, and the presence of giant biobank operators. However, the Asia-Pacific (APAC) region will experience tremendous growth because of the growing healthcare infrastructure, increasing research and development activities, a high number of patients, and growing governmental assistance towards precision medicine.

Some major players running in the market include Thermo Fisher Scientific Inc., Merck KGaA, Qiagen, Hamilton Company, Danaher Corporation, Becton, Dickinson, and Company (BD), Charles River Laboratories, Lonza, Stemcell Technologies, and Promocell GmbH.